Product Description
Sorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a607051.html)
Mechanisms of Action: TK Inhibitor,VEGFR Inhibitor,RAFk Inhibitor,PGFR Inhibitor,Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Costa Rica, Croatia, Czech Republic, Egypt, Estonia, Finland, France, Germany, Greece, India, Israel, Italy, Japan, Korea, Malaysia, New Zealand, Philippines, Poland, Puerto Rico, Romania, Russia, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: Hepatocellular Carcinoma
Phase 2: Acute Myeloid Leukemia|Biphenotypic Acute Leukemia|Colorectal Cancer|Hepatitis A|Hepatitis B|Hepatitis C|Kidney Cancer|Liver Cancer|Myelodysplastic Syndrome|Myeloproliferative Disorders|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Preleukemia
Phase 1: Brain Cancer|Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| WGI0301-P2G-01 | P2 |
Not yet recruiting |
Hepatocellular Carcinoma |
2026-08-01 |
|
| jRCT2031210045 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2026-03-31 |
|
| IMbrave251 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2025-07-09 |
|
| MO42541 | P3 |
Unknown Status |
Hepatocellular Carcinoma |
2025-06-13 |